Bioabsorbable Staple Line Reinforcement in Colorectal,Coloanal and Ileoanal Anastomoses

This study has been terminated.
(Per SAP)
Information provided by (Responsible Party):
W.L.Gore & Associates Identifier:
First received: April 18, 2008
Last updated: September 2, 2014
Last verified: September 2014
The primary purpose of this prospective, randomized multicenter center study is to evaluate and compare the outcomes of colorectal, coloanal and ileoanal anastomoses reinforced with a bioabsorbable staple line reinforcement material compared with standard non-reinforced colorectal, coloanal and ileoanal techniques with respect to the incidence of postoperative anastomotic leakage, anastomotic stricture and time to ileostomy closure, if applicable.

Condition Intervention
Rectal Cancer
Ulcerative Colitis
Familial Adenomatous Polyposis
Device: GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement
Procedure: Staple line without reinforcement

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy of Bioabsorbable Staple Line Reinforcement in Colorectal, Coloanal and Ileoanal Anastomoses: A Prospective Randomized Study

Resource links provided by NLM:

Further study details as provided by W.L.Gore & Associates:

Primary Outcome Measures:
  • Proportion of Subjects Who Experience a Clinical and/or Radiologic Anastomotic Leak [ Time Frame: completion of procedure through 4-12 weeks post procedure ] [ Designated as safety issue: No ]
    The primary endpoint for the study is the proportion of subjects who experience a clinical and/or radiologic anastomotic leak through 4 - 12 weeks post procedure.

Secondary Outcome Measures:
  • Identify and Compare the Rate of Anastomotic Stenosis Associated With Circular Stapled Anastomoses Constructed With and Without CBSG. [ Time Frame: post operative ] [ Designated as safety issue: No ]
  • Determine the Rate of Significant Staple Line Hemorrhage With and Without the Use of CBSG in Circular Stapled Anastomoses [ Time Frame: post operative ] [ Designated as safety issue: No ]
  • Provide a Cost/Benefit Analysis With Regard to the Use of CBSG in Stapled Circular Anastomoses [ Time Frame: study completion ] [ Designated as safety issue: No ]
  • Determine the Efficacy and Further Substantiate Safety of CBSG Used in Conjunction With Circular Staplers When Performing High-risk Colorectal, Coloanal, and Ileoanal Anastomoses. [ Time Frame: study completion ] [ Designated as safety issue: No ]

Enrollment: 258
Study Start Date: April 2008
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Device
GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular staplers
Device: GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement
Colorectal, coloanal, and ileoanal anastomotic staple line reinforcement with GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular stapler
Procedure/Surgery: colorectal, coloanal, and ileoanal anastomotic staple line without reinforcement
Procedure: Staple line without reinforcement
colorectal and coloanal anastomotic staple line without reinforcement

Detailed Description:
This is a randomized prospective trial that compares the use of GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement (CBSG) to standard stapling techniques in colorectal resections. The potential exists to utilize CBSG as a means of lowering the rate of post-operative anastomotic leakage and bleeding in high-risk colorectal, coloanal, and ileoanal anastomoses.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects who will undergo restorative proctectomy or proctocolectomy (<10 cm from anal verge) with a low circular stapled colorectal, coloanal or ileoanal anastomosis with or without reservoir, including treatment for rectal cancer, ulcerative colitis, familial adenomatous polyposis

    , diverticulitis, perforation of the bowel/trauma.

  • Subjects undergoing Hartmann's reversal with restorative proctectomy (<10 cm from the anal verge).
  • Subjects may or may not have a diverting loop ileostomy as a component of their initial surgery.
  • Subjects who meet the requirements of number 1 and 2, and are being treated for rectal cancer may or may not have preoperative chemoradiation therapy in the treatment of their rectal cancer.

Exclusion Criteria:

  • Subjects being treated for rectal cancer with a diagnosis of inflammatory bowel disease.
  • Subjects who have significant intraoperative hypotension or cardiac events.
  • Subjects with collagen vascular disease, coagulopathy, significant renal or hepatic dysfunction (creatinine >1.6 or liver enzymes > 50% upper limit of normal values).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00663819

United States, Alabama
University of South Alabama
Mobile, Alabama, United States, 36617
United States, California
University of Southern California, Keck School of Medicine
Los Angeles, California, United States, 90033
United States, Florida
University of South Florida-Cleveland Clinic Florida
Weston, Florida, United States, 33331
United States, Illinois
Advocate Healthcare/Good Shepard Hospital
Barrington, Illinois, United States, 60010
John Stroger Hospital of Cook County
Chicago, Illinois, United States, 60612
Peoria Surgical Group
Peoria, Illinois, United States, 61606
United States, Indiana
Colon and Rectal Surgery-NEICRS Group
Fort Wayne, Indiana, United States, 46845
Kenderick Regional Center
Indianapolis, Indiana, United States, 46237
United States, Michigan
Spectrum Health -Ferguson Group
Grand Rapids, Michigan, United States, 49503
United States, Minnesota
Duluth Clinic
Duluth, Minnesota, United States, 55805
United States, New York
Albany Medical College
Albany, New York, United States, 12208
St. Lukes-Roosevelt Hospital Center
New York, New York, United States, 10019
New York Presbyterian Hospital
New York, New York, United States, 10032
United States, Ohio
University Hospitals of Cleveland, Case Medical Center
Cleveland, Ohio, United States, 44106-5047
United States, Texas
Texas Endosurgery Institute
San Antonio, Texas, United States, 78222
United States, Utah
University of Utah Health Sciences Center and Huntsman Cancer Hospital
Salt Lake City, Utah, United States, 84132
Sponsors and Collaborators
W.L.Gore & Associates
Principal Investigator: Anthony J Senagore, MD, MBA, MS University of Southern California, Keck School of Medicine
  More Information

Responsible Party: W.L.Gore & Associates Identifier: NCT00663819     History of Changes
Other Study ID Numbers: 2008-109  CS150 
Study First Received: April 18, 2008
Results First Received: August 21, 2014
Last Updated: September 2, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by W.L.Gore & Associates:
Low anterior colon resection
Rectal Cancer

Additional relevant MeSH terms:
Adenomatous Polyposis Coli
Colitis, Ulcerative
Adenomatous Polyps
Colonic Diseases
Colorectal Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Genetic Diseases, Inborn
Inflammatory Bowel Diseases
Intestinal Diseases
Intestinal Neoplasms
Intestinal Polyposis
Intraabdominal Infections
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplastic Syndromes, Hereditary processed this record on May 30, 2016